231 related articles for article (PubMed ID: 26172299)
1. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
2. MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer.
Barsoum FS; Awad AS; Hussein NH; Eissa RA; El Tayebi HM
Pathol Res Pract; 2020 Dec; 216(12):153274. PubMed ID: 33171372
[TBL] [Abstract][Full Text] [Related]
3. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.
Frierson HF; Moskaluk CA; Powell SM; Zhang H; Cerilli LA; Stoler MH; Cathro H; Hampton GM
Hum Pathol; 2003 Jun; 34(6):605-9. PubMed ID: 12827615
[TBL] [Abstract][Full Text] [Related]
4. Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database.
Moek KL; Fehrmann RSN; van der Vegt B; de Vries EGE; de Groot DJA
Am J Pathol; 2018 Sep; 188(9):1973-1981. PubMed ID: 29935166
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
[TBL] [Abstract][Full Text] [Related]
8. NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer.
Hussein NH; Eissa RA; de Bruyn M; El Tayebi HM
Life Sci; 2022 Jun; 299():120523. PubMed ID: 35378140
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin expression is associated with poor outcomes in breast cancer.
Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin‑specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3‑treated self‑differentiated dendritic cells.
Jirapongwattana N; Thongchot S; Chiraphapphaiboon W; Chieochansin T; Sa-Nguanraksa D; Warnnissorn M; Thuwajit P; Yenchitsomanus PT; Thuwajit C
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35616135
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
14. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
15. A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
Del Bano J; Florès-Florès R; Josselin E; Goubard A; Ganier L; Castellano R; Chames P; Baty D; Kerfelec B
Front Immunol; 2019; 10():1593. PubMed ID: 31354732
[TBL] [Abstract][Full Text] [Related]
16. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c
Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
Adv Ther; 2020 Dec; 37(12):5023-5031. PubMed ID: 33052561
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Reyes C; Jorda M; Gomez-Fernández C
Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
[TBL] [Abstract][Full Text] [Related]
20. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
